STARTAR Trial: Systemic Therapy in Salvage Setting for Prostate Cancer- Tian Zhang

November 28, 2018

(Length of Discussion: 8 min)

Tian Zhang discusses with Alicia Morgans the STARTAR trial, a phase 2 enrolling high risk prostate cancer patients with Gleason 7 T3 or Gleason 8-10 who have developed PSA recurrence and adding systemic agents to standard of care with the goal of extending the lives of this patient population. They discuss logistics for patients who may qualify for this trial.


Tian Zhang, MD, Assistant Professor of Medicine in the Division of Medical Oncology and the Department of Medicine and a member of the Duke Cancer Institute

Alicia Morgans, MD, MPH